Citius Pharmaceuticals Earns 'Buy' Rating from D. Boral Capital

Analysts reissue 'buy' rating and $6.00 price target for CTXR stock.

Mar. 11, 2026 at 6:39pm

Got story updates? Submit your updates here. ›

Citius Pharmaceuticals (NASDAQ:CTXR) had its 'buy' rating reaffirmed by stock analysts at D. Boral Capital, who also maintained a $6.00 price target on the stock. The analysts' research note was published on Wednesday, according to Benzinga.

Why it matters

This positive rating and price target from D. Boral Capital could boost investor confidence in Citius Pharmaceuticals, a clinical-stage specialty pharmaceutical company focused on developing critical care products and novel drug delivery systems.

The details

In addition to the 'buy' rating from D. Boral Capital, Citius Pharmaceuticals has received a 'hold' rating from Wall Street Zen and a 'sell (e+)' rating from Weiss Ratings. Overall, the company has an average 'Hold' rating from analysts, with a consensus price target of $6.00.

  • Citius Pharmaceuticals last reported quarterly earnings on February 13, 2026.

The players

Citius Pharmaceuticals

A clinical-stage specialty pharmaceutical company focused on developing critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey and trades on the NASDAQ under the symbol CTXR.

D. Boral Capital

A stock analysis firm that reissued a 'buy' rating and $6.00 price target for Citius Pharmaceuticals.

Wall Street Zen

A research firm that upgraded Citius Pharmaceuticals from a 'strong sell' rating to a 'hold' rating.

Weiss Ratings

A research firm that maintained a 'sell (e+)' rating on Citius Pharmaceuticals.

Got photos? Submit your photos here. ›

The takeaway

The positive rating and price target from D. Boral Capital could provide a boost to Citius Pharmaceuticals as it continues to develop its pipeline of critical care products and novel drug delivery systems. However, the company still faces a mixed analyst outlook, with a 'hold' average rating and varying price targets.